End-of-day quote
Shanghai S.E.
06:00:00 2024-05-30 pm EDT
|
5-day change
|
1st Jan Change
|
49.8
CNY
|
+0.83%
|
|
-1.97%
|
-16.16%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,889
|
5,324
|
7,940
|
7,654
|
6,417
|
-
|
-
|
Enterprise Value (EV)
1 |
5,889
|
5,324
|
7,940
|
7,654
|
6,417
|
6,417
|
6,417
|
P/E ratio
|
18.1
x
|
17.6
x
|
21.2
x
|
18.4
x
|
13.9
x
|
10.7
x
|
9.38
x
|
Yield
|
-
|
-
|
-
|
2.16%
|
2.59%
|
3.15%
|
3.86%
|
Capitalization / Revenue
|
1.32
x
|
-
|
-
|
0.84
x
|
0.6
x
|
0.46
x
|
0.41
x
|
EV / Revenue
|
1.32
x
|
-
|
-
|
0.84
x
|
0.6
x
|
0.46
x
|
0.41
x
|
EV / EBITDA
|
16.3
x
|
-
|
-
|
10.6
x
|
6.59
x
|
5.51
x
|
4.61
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.43
x
|
-
|
-
|
2.68
x
|
2.03
x
|
1.8
x
|
1.63
x
|
Nbr of stocks (in thousands)
|
116,441
|
117,499
|
128,911
|
128,849
|
128,849
|
-
|
-
|
Reference price
2 |
50.58
|
45.31
|
61.59
|
59.40
|
49.80
|
49.80
|
49.80
|
Announcement Date
|
4/14/21
|
4/27/22
|
4/26/23
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4,466
|
-
|
-
|
9,081
|
10,768
|
13,920
|
15,719
|
EBITDA
1 |
361
|
-
|
-
|
719.7
|
973.5
|
1,165
|
1,392
|
EBIT
1 |
292.3
|
-
|
-
|
522.1
|
568.9
|
741.6
|
871.4
|
Operating Margin
|
6.54%
|
-
|
-
|
5.75%
|
5.28%
|
5.33%
|
5.54%
|
Earnings before Tax (EBT)
1 |
300.5
|
-
|
-
|
522.7
|
608.9
|
761.1
|
911.4
|
Net income
1 |
251.1
|
300.5
|
363.4
|
414.4
|
460.2
|
601
|
684.7
|
Net margin
|
5.62%
|
-
|
-
|
4.56%
|
4.27%
|
4.32%
|
4.36%
|
EPS
2 |
2.799
|
2.580
|
2.900
|
3.220
|
3.570
|
4.660
|
5.310
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
1.285
|
1.290
|
1.570
|
1.920
|
Announcement Date
|
4/14/21
|
4/27/22
|
4/26/23
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
31.8%
|
-
|
-
|
15.2%
|
14.6%
|
16.8%
|
17.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
6.26%
|
6.68%
|
7.06%
|
Assets
1 |
-
|
-
|
-
|
-
|
7,351
|
8,997
|
9,699
|
Book Value Per Share
2 |
14.70
|
-
|
-
|
22.20
|
24.50
|
27.70
|
30.60
|
Cash Flow per Share
2 |
2.720
|
-
|
-
|
7.950
|
8.930
|
8.330
|
9.720
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/14/21
|
4/27/22
|
4/26/23
|
4/26/24
|
-
|
-
|
-
|
Last Close Price
49.8
CNY Average target price
62.48
CNY Spread / Average Target +25.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.16% | 879M | | -37.88% | 13.28B | | -33.12% | 11B | | -22.64% | 7.39B | | +12.54% | 6.32B | | -11.17% | 5.77B | | +73.98% | 4.97B | | -4.38% | 4.54B | | -9.20% | 3.83B | | -19.40% | 3.15B |
Other Drug Retailers
|